GlassScriptPhysician profile
David C Beard
NPI 1982600201
$2,844.66
in general payments reported to CMS, 2019-2025
25 companies · $549 in 2025
The $549 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $164 · 2021: $133 · 2022: $437 · 2023: $621 · 2024: $941 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,111.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $607.09 | 2020-2024 | Xarelto |
| Kestra Medical Technology Services, INC. | $456.11 | 2023-2025 | Assure Wcd |
| Novartis Pharmaceuticals Corporation | $307.96 | 2022-2025 | |
| Amgen INC. | $235.90 | 2020-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $113.07 | 2020-2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $112.99 | 2020-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $109.89 | 2021-2024 | Farxiga |
| Boston Scientific Corporation | $108.60 | 2024-2025 | Watchman Flx |
| Abbott Laboratories | $91.42 | 2021-2024 | Cardiomems, Mitraclip |
| Heartflow, INC. | $87.05 | 2022-2024 | Ffrct |
| Novo Nordisk INC | $74.94 | 2025 | Wegovy, Ozempic |
| Abiomed | $71.85 | 2020-2025 | Impella |
| Kiniksa Pharmaceuticals International, Plc | $71.13 | 2024 | Arcalyst |
| Lantheus Medical Imaging, INC. | $49.53 | 2020-2022 | |
| Scpharmaceuticals INC. | $47.65 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $46.59 | 2025 | Flowtriever |
| Medtronic, INC. | $45.65 | 2024 | Symplicity G3 |
| Merck Sharp & Dohme LLC | $39.51 | 2023-2024 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $38.88 | 2022 | |
| Irhythm Technologies, INC. | $29.22 | 2024 | Zio Monitor, Zio Xt Patch |
| Lexicon Pharmaceuticals, INC. | $25.16 | 2024 | Inpefa |
| Cvrx, INC. | $23.48 | 2025 | Barostim Neo System |
| Vital Connect, INC | $22.47 | 2024 | Vitalpatch Rtm |
| Esperion Therapeutics, INC. | $14.46 | 2025 | Nexletol |
| Kiniksa Pharmaceuticals, LTD. | $14.06 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Beard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.